Advertisement


Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: New Phase II Data on Cabozantinib and Checkpoint Inhibitor Therapy

2023 ASCO Genitourinary Cancers Symposium

Advertisement

Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discusses interim results from the CaboPoint study, which evaluated cabozantinib as second-line treatment in patients with unresectable, locally advanced or metastatic renal cell carcinoma with a clear cell component. Disease in the study participants had progressed after prior treatment with ipilimumab and nivolumab in combination or combined with VEGF-targeted therapy. (Abstract 606).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Standard of care for renal cell carcinoma is combination therapy, meaning in patients with clear cell RCC, we have access either to a combination of doublet IO, namely nivolumab plus ipilimumab, or a combination of VGF targeting plus an immune checkpoint, such as axitinib, pembrolizumab, cabozantinib, nivolumab, or lenvatinib, pembrolizumab as well. Right now, what we don't know is what we should do in patient who failed first line therapy, meaning having disease progression under first line therapy. The purpose of CaboPoint study that has been presented at ASCO GU meeting 2023 is to investigate cabozantinib activity after first line combination failure. The study has been designed to assess activity and safety of cabozantinib single agent, so it's a Phase II, a non-randomized Phase II with two cohorts. Cohort A, patient who had failed nivolumab plus ipilimumab and Cohort B, patient who had failed VGF plus TKI regimen. What has been presented at this meeting is the interim analysis of CaboPoint study. This pre-plan analysis was designed to be performed when 80% of cohort bay had been enrolled and for which we had more than three months follow-up. So 88 patients are part of this analysis. Primary endpoint is response rate, and the key message is that with cabozantinib single agent, we are able to reach a response rate of almost 30% divided in 32% in Cohort A and 25% in Cohort B. Of course, there was no new safety signal with cabozantinib single agent. This study is important because it is the first time we have cabozantinib pure second-line data after a doublet with an IO-based first-line regimen. What is needed now is to know with further follow-up the PFS and overall survival within this study, and that will be the subject of further analysis. What we also would like to know, is there anything we should add on top of cabozantinib? And that's the topic of the CONTACT-03 study that is still pending to know if there is an added value of sustained PD-L1 inhibition, for instance. So to summarize, CaboPoint is the first prospective study of cabozantinib as a pure second line after combination therapy in first line, showing you response rates of 30% for a single-agent TKI. And it means our patient, including those who did progress under first line, should be offered a second line therapy.

Related Videos

Bladder Cancer

Aristotelis Bamias, MD, on Urothelial Carcinoma: Final Overall Survival Analysis of Atezolizumab Monotherapy vs Chemotherapy

Aristotelis Bamias, MD, of the National and Kapodistrian University of Athens, discusses results from the phase III IMvigor130 study, which suggest that atezolizumab monotherapy continues to show better tolerability vs chemotherapy for patients with untreated locally advanced or metastatic urothelial carcinoma. (Abstract LBA441).

Bladder Cancer

Vadim S. Koshkin, MD, and Tanya Jindal, BS, BA, on Urothelial Carcinoma: Biomarkers of Response to Enfortumab Vedotin-ejfv

Vadim S. Koshkin, MD, and Tanya Jindal, BS, BA, both of the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discuss results from the retrospective UNITE study of biomarkers of response to the antibody-drug conjugate enfortumab vedotin-ejfv in patients with advanced urothelial carcinoma. Enfortumab vedotin is used widely in treatment-refractory disease, but there have been limited data available on biomarkers that may predict outcomes with this treatment. The UNITE study has now identified several potential biomarkers that need to be validated to help inform clinical decision-making and therapy sequencing. (Abstract 450).

Kidney Cancer

Michael B. Atkins, MD, on Renal Cell Carcinoma: Phase II Findings on Nivolumab and Ipilimumab

Michael B. Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, discusses treatment-free survival outcomes from the HCRN GU16-260-Cohort A study of patients with previously untreated advanced clear cell renal cell carcinoma who received nivolumab and salvage nivolumab plus ipilimumab. The regimen appears to result in substantial treatment-free survival with few treatment-related adverse events. (Abstract 604).

Prostate Cancer

Scott T. Tagawa, MD, on Prostate Cancer: Phase II Results on Ketoconazole, Hydrocortisone, and an Anti-PSMA Antibody

Scott T. Tagawa, MD, of Weill Cornell Medicine, NewYork-Presbyterian Hospital, discusses study results showing that, the anti-PSMA (prostate-specific membrane antigen) monoclonal antibody J591 with ketoconazole and hydrocortisone, when radiolabeled with lutetium-177, leads to improved 18-month metastasis-free survival vs radiolabeling with indium-111 in patients with nonmetastatic (M0) castration-resistant prostate cancer. This supports the development of anti-PSMA radioimmunotherapy, although the optimal radionuclide and targeting agent are unknown. (Abstract LBA21).

Bladder Cancer

Matt D. Galsky, MD, on Urothelial Carcinoma: New Study Results on Atezolizumab, Platinum, and Gemcitabine

Matt D. Galsky, MD, of the Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses final overall survival data from the phase III IMvigor130 study, which compared atezolizumab versus placebo, both of which were paired with platinum and gemcitabine in the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma. (Abstract LBA440).

Advertisement

Advertisement




Advertisement